-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Eli Lilly and Boehringer Ingelheim jointly announced that the U.
Enpagliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken orally once a day.
▲The primary and critical secondary endpoint data of the EMPEROR-Preserved trial (picture source: reference [2])
This supplementary new drug application is based on the positive results of the Phase 3 clinical trial EMPEROR-Preserved
Reference materials:
[1] US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction.
[2] Anker et al.